Since down-regulation of REST is responsible for signaling the NED of PCa, the development of β-TrCP specific inhibitors may provide a new strategy to increase the effectiveness of ADT treatment by prevention NED during ADT treatment. This evidence concerns the gene REST and posterior cortical atrophy.